<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073718</url>
  </required_header>
  <id_info>
    <org_study_id>HCB/2021/0060</org_study_id>
    <nct_id>NCT05073718</nct_id>
  </id_info>
  <brief_title>Acetylsalicylic Acid in COVID-19 (ASA-SARS)</brief_title>
  <acronym>ASA-SARS</acronym>
  <official_title>Efficacy of Low Dose Acetylsalicylic Acid in Preventing Adverse Maternal and Perinatal Outcomes in SARS-CoV-2 Infected Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barcelona Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario de Torrejón,Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Infanta Leonor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopsital Central de Maputo, Mozambique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barcelona Institute for Global Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SARS-CoV-2 infection in pregnancy is associated with poor maternal and perinatal outcomes.&#xD;
      One explanation is the pregnancy-associated prothrombotic status, which may increase during&#xD;
      infection, leading to placental and vascular complications. Administration of low-dose&#xD;
      acetylsalicylic acid (LDASA) has shown to improve maternal and perinatal outcomes in women at&#xD;
      high-risk of endothelial and placental complications. However, there are no data on the&#xD;
      effect of adding LDASA to low molecular weight heparin (LMWH)-which is the standard of care-&#xD;
      in preventing complications in SARS-CoV-2- infected pregnant women. This is a randomized,&#xD;
      double-blinded, placebo-controlled multicentre trial including 398 SARS-CoV-2-infected&#xD;
      pregnant women with the main objective of evaluating the efficacy of adding daily LDASA to&#xD;
      low molecular weight heparin (LMWH) from the first or second trimester up to 36 weeks'&#xD;
      gestation in SARS-CoV-2-infected pregnant women in reducing the incidence of adverse maternal&#xD;
      and perinatal outcomes. Pregnant women undergoing routine first or second trimester blood&#xD;
      tests will have a SARS-CoV-2 rapid antigen test done if they agree to participate. Women with&#xD;
      a positive SARS-CoV-2 rapid antigen test will be further tested with a confirmatory&#xD;
      SARS-CoV-2 PCR test. In case of being also positive for the SARS-CoV-2 PCR test, she will be&#xD;
      randomised 1:1 to receive, additionally to LMWH for at least 10 days, daily LDASA (150 mg) or&#xD;
      placebo, up to 36 weeks of pregnancy. Women will be followed-up for the duration of the&#xD;
      intervention and the pregnancy outcome will be registered. The findings of this study will&#xD;
      contribute to reduce SARS-CoV-2- related complications in a highly vulnerable group to the&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double-blind placebo-controlled multicentre clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study tablets will be identically packaged in small opaque bottles. All study personnel, investigators and the participants will remain blinded throughout the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of composite adverse maternal and perinatal adverse outcome including fetal death, preterm preeclampsia, maternal thromboembolic complications, placental abruption, preterm birth and small for gestational age.</measure>
    <time_frame>up to 37 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of SARS-CoV-2 infection and COVID-19 disease during pregnancy</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19-related admissions</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause admissions</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause outpatient attendances</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of symptoms-signs of COVID-19</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of preeclampsia</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal thromboembolic complications and placental abruption</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal mortality rate</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of histological placental abnormalities in SARS-CoV-2 infected pregnant women.</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of preterm birth (&lt;37 weeks of gestational age)</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of small for gestational age</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of embryo and foetal losses (miscarriages and stillbirths)</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of adverse perinatal outcome</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality rate</measure>
    <time_frame>up to 37 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">199</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>LDASA + prophylactic doses of LMWH (n=199)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + prophylactic doses of LMWH (n=199)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose acetylsalicylic acid</intervention_name>
    <description>In case of being also positive for the SARS-CoV-2 PCR test, she will be randomised 1:1 to receive, additionally to LMWH for at least 10 days, daily LDASA (150 mg) or placebo, up to 36 weeks of pregnancy.</description>
    <arm_group_label>LDASA + prophylactic doses of LMWH (n=199)</arm_group_label>
    <other_name>Asprin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo + prophylactic doses of LMWH (n=199)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with a positive SARS-CoV-2 antigen test and a confirmatory positive&#xD;
             SARS-CoV-2 PCR test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  on regular ASA administration&#xD;
&#xD;
          -  on long-term non-steroidal anti-inflammatory medication&#xD;
&#xD;
          -  bleeding disorders such as Von Willebrand's disease&#xD;
&#xD;
          -  history of peptic ulceration&#xD;
&#xD;
          -  history of hypersensitivity to ASA&#xD;
&#xD;
          -  participation in another clinical trial&#xD;
&#xD;
          -  inability to cooperate with the requirements of the study&#xD;
&#xD;
          -  severe COVID-19 disease (with any of the following: respiratory rate &gt; 30 breaths/min;&#xD;
             severe respiratory distress; SpO2 ≤ 93% on room air; acute respiratory distress&#xD;
             syndrome; sepsis with acute organ dysfunction).&#xD;
&#xD;
          -  treatment resistant hyperemesis gravidarum&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Garcia, Dr.</last_name>
    <phone>+34 93 227 5400</phone>
    <email>laura.garcia@isglobal.org</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-COV2</keyword>
  <keyword>Acetylsalicylic acid</keyword>
  <keyword>Asprin</keyword>
  <keyword>ASA</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Perinatal</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

